Mesoblast (ASX:MSB) has repaid its senior secured loan from Oaktree Capital Management and partially settled its subordinated royalty facility with NovaQuest Capital Management.
Memphasys (ASX:MEM) has secured CE Mark approval for its Felix automated sperm selection system under the EU Medical Device Regulation.
Enlitic (ASX:ENL) has secured commitments for a capital raise of $8 million through the issuance of secured convertible notes to a group of sophisticated investors.
Adherium (ASX:ADR) exceeded its key commercial milestones for calendar year 2025, with total device shipments surpassing 4,666 units.
Dimerix (ASX:DXB) has received feedback from the US Food and Drug Administration on its ACTION3 Phase 3 trial of DMX-200.
Paradigm Biopharmaceuticals (ASX:PAR) has confirmed that it has achieved approximately 25% of target recruitment in its pivotal Phase 3 PARA_OA_012 clinical trial.
Ramsay Health Care (ASX:RHC) has agreed to acquire the assets and operations of National Capital Private Hospital in Canberra.
CONNEǪT Health (ASX:CǪT) has secured $3.1 million (before costs) through a placement of new fully paid ordinary shares at $0.045 per share.
Reece (ASX:REH) has announced a $50 million increase to its on-market share buyback, lifting the total target to $85 million.
Health Canada has approved Neuren Pharmaceuticals' (ASX:NEU) clinical trial application for the Koala Phase 3 clinical trial.
Dimerix (ASX:DXB) confirmed that BioMarin Pharmaceutical (NASDAQ:BMRN) entered into a definitive agreement to acquire its US commercial licensing partner, Amicus Therapeutics (NASDAQ:FOLD)
Regis Healthcare (ASX:REG) announced that Dr Linda Mellors will resign as CEO and Managing Director after more than six years at the helm.
-1-640x360.png&w=3840&q=75)